Literature DB >> 12766129

Relation between serum 3-deoxyglucosone and development of diabetic microangiopathy.

Hitomi Kusunoki1, Satoshi Miyata, Takeshi Ohara, Bing-Fen Liu, Atsuko Uriuhara, Hiroshi Kojima, Kotaro Suzuki, Hiroyuki Miyazaki, Yumiko Yamashita, Kayo Inaba, Masato Kasuga.   

Abstract

OBJECTIVE: 3-Deoxyglucosone (3-DG), a highly reactive intermediate of the glycation reaction, has been suggested to contribute to the development of diabetes complications. To verify this hypothesis, we assessed the relation between serum 3-DG concentrations and the severity of diabetic microangiopathy in diabetic patients. RESEARCH DESIGN AND METHODS: We conducted a high-performance liquid chromatography assay to determine the serum 3-DG concentrations of 110 diabetic patients with different degrees of severity of diabetic microangiopathy and 57 age-matched control subjects.
RESULTS: The fasting serum 3-DG level in diabetic patients was significantly (P < 0.001) higher than that in control subjects (353 +/- 110 vs. 199 +/- 53 nmol/l). The 3-DG levels were significantly (P < 0.001) elevated even in the diabetic patients showing normoalbuminuria (n = 62, 322 +/- 79 nmol/l) compared with control subjects. The 3-DG levels were further elevated in the patients with microalbuminuria (n = 30, 383 +/- 146 nmol/l) and overt proteinuria (n = 18, 410 +/- 100 nmol/l) (P = 0.027 and P < 0.001 vs. normoalbuminuria group, respectively). This phenomenon was basically reproduced in a category of retinopathy. Furthermore, the diabetic patients with low nerve conduction velocity showed a tendency to display higher 3-DG levels.
CONCLUSIONS: The present results show that the fasting serum 3-DG level is elevated in diabetic patients and that the patients with relatively higher 3-DG levels were prone to suffer from more severe complications, indicating a possible association of 3-DG with diabetic microangiopathy.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12766129     DOI: 10.2337/diacare.26.6.1889

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  11 in total

1.  "NEPP" peritoneal dialysis regimen has beneficial effects on plasma CEL and 3-DG, but not pentosidine, CML, and MGO.

Authors:  Caatje Y le Poole; Frans J van Ittersum; Rob M Valentijn; Tom Teerlink; Bengt Lindholm; Piet M Ter Wee; Casper G Schalkwijk
Journal:  Perit Dial Int       Date:  2011-05-31       Impact factor: 1.756

Review 2.  Trends in advanced glycation end products research in diabetes mellitus and its complications.

Authors:  José D Méndez; Jianling Xie; Montserrat Aguilar-Hernández; Verna Méndez-Valenzuela
Journal:  Mol Cell Biochem       Date:  2010-03-23       Impact factor: 3.396

3.  Infusion fluids contain harmful glucose degradation products.

Authors:  Anna Bryland; Marcus Broman; Martin Erixon; Bengt Klarin; Torbjörn Lindén; Hans Friberg; Anders Wieslander; Per Kjellstrand; Claudio Ronco; Ola Carlsson; Gabriela Godaly
Journal:  Intensive Care Med       Date:  2010-04-16       Impact factor: 17.440

4.  Citrate treatment reduces endothelial death and inflammation under hyperglycaemic conditions.

Authors:  Anna Bryland; Anders Wieslander; Ola Carlsson; Thomas Hellmark; Gabriela Godaly
Journal:  Diab Vasc Dis Res       Date:  2011-11-01       Impact factor: 3.291

5.  Association between Advanced Glycation End Products and Impaired Fasting Glucose: Results from the SALIA Study.

Authors:  Tom Teichert; Anne Hellwig; Annette Peßler; Michael Hellwig; Mohammad Vossoughi; Dorothea Sugiri; Andrea Vierkötter; Thomas Schulte; Juliane Freund; Michael Roden; Barbara Hoffmann; Tamara Schikowski; Christian Luckhaus; Ursula Krämer; Thomas Henle; Christian Herder
Journal:  PLoS One       Date:  2015-05-27       Impact factor: 3.240

Review 6.  Dicarbonyls and Advanced Glycation End-Products in the Development of Diabetic Complications and Targets for Intervention.

Authors:  Sebastian Brings; Thomas Fleming; Marc Freichel; Martina U Muckenthaler; Stephan Herzig; Peter P Nawroth
Journal:  Int J Mol Sci       Date:  2017-05-05       Impact factor: 5.923

Review 7.  Pleiotropic Actions of Aldehyde Reductase (AKR1A).

Authors:  Junichi Fujii; Takujiro Homma; Satoshi Miyata; Motoko Takahashi
Journal:  Metabolites       Date:  2021-05-26

Review 8.  Circulating Biomarkers of Diabetic Retinopathy: An Overview Based on Physiopathology.

Authors:  Olga Simó-Servat; Rafael Simó; Cristina Hernández
Journal:  J Diabetes Res       Date:  2016-06-08       Impact factor: 4.011

Review 9.  Glucose and Blood Pressure-Dependent Pathways-The Progression of Diabetic Kidney Disease.

Authors:  Devang M Patel; Madhura Bose; Mark E Cooper
Journal:  Int J Mol Sci       Date:  2020-03-23       Impact factor: 5.923

10.  Human carnosinase 1 overexpression aggravates diabetes and renal impairment in BTBROb/Ob mice.

Authors:  Jiedong Qiu; Thomas Albrecht; Shiqi Zhang; Sibylle J Hauske; Angelica Rodriguez-Niño; Xinmiao Zhang; Darya Nosan; Diego O Pastene; Carsten Sticht; Carolina Delatorre; Harry van Goor; Stefan Porubsky; Bernhard K Krämer; Benito A Yard
Journal:  J Mol Med (Berl)       Date:  2020-08-15       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.